{"organizations": [], "uuid": "4b8842f8d3da029445d601abdb098395dc3155f9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.menafn.com", "main_image": "http://menafn.com/images/shared/menafnlogo_sm.gif", "site_section": "http://www.menafn.com/rss/menafn_Comm_Tech_Technologies.xml", "section_title": "MENAFN.com Comm_Tech_Technologies", "url": "http://www.menafn.com/1094380244/Tissue-Regenix-ahead-of-schedule-with-US-rollout&src=RSS", "country": "", "title": "Tissue Regenix ahead of schedule with US roll-out", "performance_score": 0, "site": "menafn.com", "participants_count": 1, "title_full": "Tissue Regenix ahead of schedule with US roll-out | MENAFN.COM", "spam_score": 0.0, "site_type": "news", "published": "2015-10-12T03:00:00.000+03:00", "replies_count": 0, "uuid": "4b8842f8d3da029445d601abdb098395dc3155f9"}, "author": "ProactiveInvestors  N.America", "url": "http://www.menafn.com/1094380244/Tissue-Regenix-ahead-of-schedule-with-US-rollout&src=RSS", "ord_in_thread": 0, "title": "Tissue Regenix ahead of schedule with US roll-out", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "(MENAFN - ProactiveInvestors) Tissue Regenix (LON:TEX) is ahead of schedule with the roll-out of its skin repair product in the US the med-tech company said. The regenerative medicine group launched skin graft DermaPure in the US last year and is using both a direct sales force and distributor network to boost sales.\nDermaPure is now available under Medicare the US’s healthcare plan for the elderly to some 37mln people in in 31 US states.\nTwo distributor agreements were signed the first half that will be worth a minimum of US0.8mln in sales.\nElsewhere a replacement knee cartilage using Tissue Regenix’s cell washing technology has begun European trials while recruitment for an anterior cruciate ligament replacement trial is expected to start by the end of the year.\nChief executive Antony Odell added:“The successful implementation of our hybrid commercialisation strategy throughout the USA has meant that we are exceeding our expectations for the roll out of DermaPure; and the ongoing clinical trial for the dCELL meniscus product within the EU will allow us to gain a CE mark and expand our portfolio of products throughout 2016.”\nRevenues in the half year to July rose to £252000 (£1 ) while losses were £4mln (from 3.7mln) reflecting the increased spending in the US.\nCash at the end of the period was £24.9mln.", "external_links": [], "published": "2015-10-12T03:00:00.000+03:00", "crawled": "2015-10-13T03:32:56.987+03:00", "highlightTitle": ""}